Results 171 to 180 of about 184,542 (286)

Two Cases of Childhood Generalized Pustular Psoriasis Successfully Treated with Cyclosporine

, 2023
Jae Young Sung, Chang Yong Kim, Young Ah Cho, Da‐Ae Yu, Yang Won Lee, Yong Beom Choe   +5 more
openalex   +2 more sources

Useful Instruments for Psoriasis Patients’ Follow‐Up in Teleconsultation Setting

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Teledermatology may be beneficial for psoriasis management and a working group of the International Psoriasis Council recently outlined the value of patient questionnaires in teledermatology. Objectives Identify instruments that could optimise psoriasis evaluation when completed before a teleconsultation; assess patients’ and ...
Emmanuel Mahé, Nicole Jouan, Delphine Devulder, Pascale Zukervar, Dorian Petonnet, Gaelle Desamericq, Theo Cerceau, Stéphane Bouée, Anne Bouloc   +8 more
wiley   +1 more source

De Novo Psoriasis Following Belatacept Therapy in Transplant Recipients: Case Series. [PDF]

Clin Transplant
Im GY, Mckee KE, Flowers RH, Nishio Lucar AG, Rao S.   +4 more
europepmc   +1 more source

Disseminated tuberculosis and heart failure in a patient receiving infliximab for psoriasis

, 2014
Ercan Çalışkan, Deniz Doğan, Erol Koç, Gürol Açıkgöz, Yalçın Gökoğlan, Yavuz Çekli, Ahmet Akar   +6 more
openalex   +1 more source

Real‐World, Prospective, Multicenter Outcomes to Brodalumab Treatment in Patients With Moderate‐to‐Severe Psoriasis in Greece (The RESOLVE Study)

JEADV Clinical Practice, EarlyView.
RESOLVE was a prospective, real‐world study in patients with moderate‐to‐severe psoriasis treated with brodalumab. At Week 12, 76.4% achieved PASI ≤ 3, 53.5% PASI100, and 71.5%/54.2% achieved sPGA0/1 and sPGA 0, respectively. At Week 52, 96.1% achieved sPGA success (clear/almost clear). Furthermore, at Week 52, mean DLQI scores decreased by 12.6 ± 6.2,
Electra Nicolaidou, Pantelis Panagakis, Dimitrios Xekardakis, Natalia Rompoti, Marina Papoutsaki, Ioanna Lefaki, Kanella Kalapothakou, Despina Exadactylou, Athanasios Chaniotis, Vasiliki Chasapi, Alexander Stratigos   +10 more
wiley   +1 more source

Systemic Treatment Strategies for Patients with Psoriasis and Psoriatic Arthritis in the Setting of ANA Positivity or Lupus Spectrum Disease: A Comprehensive Systematic Review. [PDF]

Int J Mol Sci
Tjiu JW, Tsai TF.
europepmc   +1 more source

Efficacy of Ritlecitinib for Vitiligo Treatment Stratified by Baseline Demographic and Clinical Characteristics: Post Hoc Analysis of a Phase 2b Study

JEADV Clinical Practice, EarlyView.
This post hoc analysis examined the efficacy of ritlecitinib in subgroups of patients with vitiligo, defined by demographic and clinical characteristics. Patients completed the dose‐ranging and extension periods of the phase 2b study (NCT03715829) of ritlecitinib.
A. G. Pandya, I. Hamzavi, P. Ghosh, K. Ezzedine, J. E. Harris, R. Adiri, S. Chen, E. Peeva, Y. Yamaguchi   +8 more
wiley   +1 more source

Design, Synthesis, and Biological Evaluation of an Orally Bioavailable, Potent, and Selective ROCK2 Inhibitor for Psoriasis Treatment

, 2023
Yun Huang, Chu-Ru Mao, Yijie Lou, Shuai Zhan, Zhe Chen, Wanjing Ding, Zhongjun Ma   +6 more
openalex   +1 more source

Dupilumab Treatment in Pemphigus: A Report of Three Cases and Literature Review

JEADV Clinical Practice, EarlyView.
ABSTRACT Pemphigus vulgaris (PV) and foliaceus (PF) are rare autoimmune blistering diseases traditionally treated with systemic corticosteroids, immunosuppressants, intravenous immunoglobulins, and rituximab. Nonetheless, a subset of patients remains refractory or has contraindications to these conventional therapies.
José Javier Mateos Rico, Marta Gutiérrez Pascual, María Dolores Caro Gutiérrez, Cristina Marcos Rodríguez, Javier de Quadros Malagón, Francisco Javier Vicente Martín   +5 more
wiley   +1 more source

Frequency of HLA class I and II in an admixed Brazilian population with psoriasis. [PDF]

An Bras Dermatol
Sampaio AL, Romana-Souza B, Monteiro H, Nogueira JS, Secco DA, Cantos GCD, Monte-Alto-Costa A, Cassia F, Carneiro S, Azulay-Abulafia L, Porto LC.   +10 more
europepmc   +1 more source